NTP-464

NTP-464 is a novel surface checkpoint protein and "multicellular orchestrator of inflammation resolution" identified by Nucleome Therapeutics through its proprietary 3D genome mapping platform. It is expressed on the surface of B cells and regulatory T cells (Tregs), where it plays a critical role in maintaining immune homeostasis. In patients with autoimmune diseases such as rheumatoid arthritis (RA), genetic variants in the non-coding "dark genome" lead to decreased expression of NTP-464 on B cells, contributing to dysregulated inflammation. Agonizing this target with a monoclonal antibody (also designated NTP-464) has been shown to inhibit B cell activation and proliferation while simultaneously enhancing the suppressive function of Tregs. This dual mechanism, which involves the induction of the anti-inflammatory enzyme IDO1, offers a first-in-class therapeutic approach for treating chronic inflammatory conditions including RA, systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD).

Other names

Novel inflammation checkpointMulticellular orchestrator of inflammation resolution

Agonist monoclonal antibody that activates the NTP-464 surface protein to resolve inflammation by inhibiting B cell activation and enhancing Treg suppressive activity.